Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J B Porter

Showing results (1-10 of 99) with videos related to

Pageof 10
Sort By:
British Journal of Haematology|November 13, 2001
Practical management of iron overloadJ B Porter
Seminars in Hematology|February 24, 2001
Deferoxamine pharmacokineticsJ B Porter
Acta Haematologica|January 1, 1996
Evaluation of new iron chelators for clinical useJ B Porter
Drug Safety|January 16, 1998
A risk-benefit assessment of iron-chelation therapyJ B Porter
Seminars in Hematology|April 23, 2005
Monitoring and treatment of iron overload: state of the art and new approachesJ B Porter
Journal of Clinical Pharmacology|October 1, 1981
Potentiation of ampicillin skin reactions by allopurinol or hyperuricemiaH Jick, J B Porter
The New England Journal of Medicine|July 21, 1983
Breast cancer and cigarette smokingJ B Porter, H Jick
Acta Haematologica|January 1, 1987
Transfusion and exchange transfusion in sickle cell anaemias, with particular reference to iron metabolismJ B Porter, E R Huehns
British Journal of Haematology|October 1, 1993
Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron poolsK P Hoyes, J B Porter
Bailliere'S Clinical Haematology|April 1, 1989
The toxic effects of desferrioxamineJ B Porter, E R Huehns
Pageof 10

Showing results (1-10 of 99) with videos related to

Sort By:
Pageof 10
British Journal of Haematology|November 13, 2001
Practical management of iron overloadJ B Porter
Seminars in Hematology|February 24, 2001
Deferoxamine pharmacokineticsJ B Porter
Acta Haematologica|January 1, 1996
Evaluation of new iron chelators for clinical useJ B Porter
Drug Safety|January 16, 1998
A risk-benefit assessment of iron-chelation therapyJ B Porter
Seminars in Hematology|April 23, 2005
Monitoring and treatment of iron overload: state of the art and new approachesJ B Porter
Journal of Clinical Pharmacology|October 1, 1981
Potentiation of ampicillin skin reactions by allopurinol or hyperuricemiaH Jick, J B Porter
The New England Journal of Medicine|July 21, 1983
Breast cancer and cigarette smokingJ B Porter, H Jick
Acta Haematologica|January 1, 1987
Transfusion and exchange transfusion in sickle cell anaemias, with particular reference to iron metabolismJ B Porter, E R Huehns
British Journal of Haematology|October 1, 1993
Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron poolsK P Hoyes, J B Porter
Bailliere'S Clinical Haematology|April 1, 1989
The toxic effects of desferrioxamineJ B Porter, E R Huehns
Pageof 10